Artwork

Contenuto fornito da Labiotech. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Labiotech o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.
Player FM - App Podcast
Vai offline con l'app Player FM !

Gene editing in the microbiome to treat acne

29:02
 
Condividi
 

Manage episode 393656470 series 3361449
Contenuto fornito da Labiotech. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Labiotech o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.

Eligo Bioscience is a gene-editing company focused on addressing diseases driven by the expression of bacterial genes from the microbiome.
Its first target is moderate to severe acne vulgaris, an inflammatory disease that affects about 3% of the global population.

This week, we talk to Xavier Duportet, CEO of Eligo Bioscience, as the company looks to head to the clinic with its acne vulgaris treatment.

00:53-02:42: About Eligo Bioscience
02:42-06:07: How are you creating a new class of transformative genetic medicine?
06:08-10:07: How important is the microbiome?
10:07-11:48: How do you account for differences in the microbiome?
11:48-13:17: What conditions are you looking to treat?
13:17-18:42: What is your EB005 platform?
18:42-21:28: How will your acne treatment be administered?
21:28-22:06: How will Eligo keep the cost of the acne treatment low?
22:06-24:36: Will your platform be applicable to other diseases?
24:36-25:52: Will a combination of treatments of the microbiome make a difference?
25:52-28:14: What will the recent funding mean to Eligo Bioscience?
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

  continue reading

Capitoli

1. Gene editing in the microbiome to treat acne (00:00:00)

2. About Eligo Bioscience (00:00:53)

3. How are you creating a new class of transformative genetic medicine?
 (00:02:42)

4. How important is the microbiome? (00:06:08)

5. How do you account for differences in the microbiome? (00:10:07)

6. What conditions are you looking to treat?
 (00:11:48)

7. What is your EB005 platform?
 (00:13:17)

8. How will your acne treatment be administered?
 (00:18:42)

9. How will Eligo keep the cost of the acne treatment low?
 (00:21:28)

10. Will your platform be applicable to other diseases?
 (00:22:06)

11. Will a combination of treatments of the microbiome make a difference?
 (00:24:36)

12. What will the recent funding mean to Eligo Bioscience? (00:25:52)

110 episodi

Artwork
iconCondividi
 
Manage episode 393656470 series 3361449
Contenuto fornito da Labiotech. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Labiotech o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.

Eligo Bioscience is a gene-editing company focused on addressing diseases driven by the expression of bacterial genes from the microbiome.
Its first target is moderate to severe acne vulgaris, an inflammatory disease that affects about 3% of the global population.

This week, we talk to Xavier Duportet, CEO of Eligo Bioscience, as the company looks to head to the clinic with its acne vulgaris treatment.

00:53-02:42: About Eligo Bioscience
02:42-06:07: How are you creating a new class of transformative genetic medicine?
06:08-10:07: How important is the microbiome?
10:07-11:48: How do you account for differences in the microbiome?
11:48-13:17: What conditions are you looking to treat?
13:17-18:42: What is your EB005 platform?
18:42-21:28: How will your acne treatment be administered?
21:28-22:06: How will Eligo keep the cost of the acne treatment low?
22:06-24:36: Will your platform be applicable to other diseases?
24:36-25:52: Will a combination of treatments of the microbiome make a difference?
25:52-28:14: What will the recent funding mean to Eligo Bioscience?
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

  continue reading

Capitoli

1. Gene editing in the microbiome to treat acne (00:00:00)

2. About Eligo Bioscience (00:00:53)

3. How are you creating a new class of transformative genetic medicine?
 (00:02:42)

4. How important is the microbiome? (00:06:08)

5. How do you account for differences in the microbiome? (00:10:07)

6. What conditions are you looking to treat?
 (00:11:48)

7. What is your EB005 platform?
 (00:13:17)

8. How will your acne treatment be administered?
 (00:18:42)

9. How will Eligo keep the cost of the acne treatment low?
 (00:21:28)

10. Will your platform be applicable to other diseases?
 (00:22:06)

11. Will a combination of treatments of the microbiome make a difference?
 (00:24:36)

12. What will the recent funding mean to Eligo Bioscience? (00:25:52)

110 episodi

Tutti gli episodi

×
 
Loading …

Benvenuto su Player FM!

Player FM ricerca sul web podcast di alta qualità che tu possa goderti adesso. È la migliore app di podcast e funziona su Android, iPhone e web. Registrati per sincronizzare le iscrizioni su tutti i tuoi dispositivi.

 

Guida rapida